Ra Pharmaceuticals Inc (NASDAQ:RARX) Insider Sells $350,694.50 in Stock

Ra Pharmaceuticals Inc (NASDAQ:RARX) insider Ramin Farzaneh-Far sold 10,595 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $33.10, for a total value of $350,694.50. Following the transaction, the insider now owns 8,521 shares in the company, valued at $282,045.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ:RARX opened at $34.43 on Friday. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -16.71 and a beta of 1.23. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.10 and a quick ratio of 20.10. The stock’s 50-day moving average price is $26.85. Ra Pharmaceuticals Inc has a 12 month low of $8.67 and a 12 month high of $34.50.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. As a group, research analysts predict that Ra Pharmaceuticals Inc will post -1.98 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. FMR LLC grew its stake in shares of Ra Pharmaceuticals by 12.9% in the first quarter. FMR LLC now owns 466,834 shares of the company’s stock valued at $10,457,000 after buying an additional 53,445 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Ra Pharmaceuticals in the first quarter valued at about $229,000. Group One Trading L.P. acquired a new stake in shares of Ra Pharmaceuticals in the first quarter valued at about $34,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Ra Pharmaceuticals in the first quarter valued at about $570,000. Finally, EAM Global Investors LLC acquired a new stake in shares of Ra Pharmaceuticals in the first quarter valued at about $1,009,000. Institutional investors and hedge funds own 94.97% of the company’s stock.

Several equities research analysts have commented on the company. Robert W. Baird assumed coverage on TAIWAN LIPOSOME/S in a research note on Thursday, June 20th. They set an “outperform” rating for the company. Raymond James dropped their price target on Marathon Petroleum from $90.00 to $85.00 and set a “strong-buy” rating for the company in a research note on Wednesday, April 10th. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Svb Leerink assumed coverage on Ra Pharmaceuticals in a research note on Wednesday, May 22nd. They set an “outperform” rating and a $33.00 price target for the company. Finally, Zacks Investment Research lowered Hallmark Financial Services from a “buy” rating to a “hold” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, ten have issued a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $37.73.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: Price to Earnings Ratio (PE)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.